Venture capitalists and large drugmakers seeking to boost their stem-cell research capabilities are likely to invest in the field, according to the report. One potential target for big drugmakers is International Stem Cells, which is currently performing early-stage testing of treatments using stem cells.
- More on GSK
- Stocks Under $10: Two Buys
- 3 Stocks I Saw on TV
- Stocks Under $10: 2 Potential Buys
- Bulls Rule for Year End
- Pfizer, Berkshire Hathaway: Ratings Changes
- Bristol-Myers, Origin Lead High-Flying Stocks
- Healthcare Stocks: Safe and Speculative
- Jim Cramer's Portfolios of the Week
- 'Fast Money' Recap: Playing Defense
- Pfizer to Begin Selling Generics in Japan
- Market Activity
- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
